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The human race has been affected by the continuing 
pandemic of SARS-CoV-2, with even the farthest reaches of the 
planet testing positive for the virus. At the time of writing this, a 
novel coronavirus (COVID-19) has infected over 40 million people 
worldwide, and the global death rate has reached almost 1.2 
million[1]. However, this pandemic could potentially be 
overshadowed by a more significant threat to humankind… bacterial 
resistance to antibiotics. 
 
Incessant battle. 
Humans and microorganisms have always been in a constant 
battle with each other. However, not all of these diverse prokaryotes 
cause infection and disease. Some are beneficial in maintaining a 
homeostatic balance of microflora within our bodies. Nevertheless, 
with the dawn of the ‘antibiotic era’, humans developed a new set 
of ‘chemical weapons’ to use against pathogenic microbes. 
Unfortunately, the microbes fought back, evolving to become 
resistant to these “weapons”. 
It is an entirely natural process for bacteria to evolve 
resistance to chemicals that target it - they have been doing it for 
billions of years. However, as modern medicine has progressed, 
bacteria have become more exposed to newly developed antibiotics 
and survive. The surviving bacteria then pass down antibiotic-
resistant genes to their offspring[2]. Our misplaced reliance and 
overuse of antibiotics has compounded the problem, making 
bacteria even more robust.  
Given the evolution of antibiotic-resistant bacteria has 
overtaken the development of new antibiotics, and no new classes 
of antibiotics have been discovered for over 30 years[3], it is clear that 
the continuing COVID-19 pandemic pales into insignificance with 
what is around the corner. 
 
When treatment is an issue. 
COVID-19 (caused by virus SARS-CoV-2) is highly contagious, 
more so than any recent virus we have encountered. It is transmitted 
from person to person through a number of different pathways, like 
respiratory droplets, direct contact with the infected, and indirect 
contact with surfaces[4]. When a patient is suffering from COVID-19 
infection, opportunistic bacterial pathogens can persist and enter 
into the equation. This bacterial co-infection, along with secondary 
infection, are additional factors causing morbidity and mortality. 
From 24 separate studies that were recently conducted, 
figures have shown that 72% of hospital inpatients testing positive 
for COVID-19 were given antibiotics as a prophylactic to treat a 
suspected bacterial infection. However, only 17.8% of COVID-19 
patients were confirmed as having co-infection or developed 
secondary infections like bacterial pneumonia[5][6]. This is a 
perturbing fact, as many of these patients might have never had a 
bacterial infection, however, they were still treated with antibiotics. 
Clinicians are forced to do this in the hope of preventing patient 
death from co/secondary infections because they are unable to 
diagnose an infection in a more expeditious way. Nevertheless, the 
education regarding antibiotic stewardship in both the community 
and hospital environment (where the majority of human broad-
spectrum antibiotics are prescribed[7]) needs to be improved. 
Additionally, reluctance to use newly developed agents because it is 
more cost effective to use older antibiotics has led to antibiotic 
overuse[8]. It is these issues that have been key factors in the 
evolution of “superbugs”. 
 
Vertical & horizontal gene transfer. 
Understanding bacterial evolution and how super strains are 
mutating is paramount to tackling this issue. Bacterial organisms 
have varied mechanisms to resist the antibiotics created to destroy 
them; like the ability to produce specific enzymes that can make an 
antibiotic inactive against it. Consequently, these genetic mutations 
are passed down through vertical transfer from a parent cell to its 
offspring, making the bacteria harder to eliminate. 
There is also the issue of horizontal transfer, a process where 
a bacterial organism is able to transfer its genetic material to another 
bacterial organism that is not an offspring. During this transfer, it is 
possible that much of the bacteria’s genome is changed. Plasmid-
mediated resistance is an example of this process. Antibiotic 
resistant genes are carried on plasmids, which can be transferred 
between bacteria of the same species, or even, more worryingly, 
between different species. Moreover, this type of bacterial 
resistance to antibiotics is a far greater challenge to control. An 
example of gene transfer is Staphylococcus aureus, which was once 
easily treated by methicillin (a β-lactam penicillin class antibiotic). 
However, this bacterium evolved the ability to produce an enzyme 
called penicillinase, giving the microbe penicillin resistance. This 
resistant organism is more commonly known as MRSA (methicillin-
resistant Staphylococcus aureus).  
 
Poverty = Infection. 
Knowing how resistant bacteria are evolving is not the only 
way to curb the rising trend of superbugs. Following basic hygiene 
practises, like regularly washing hands/surfaces, using sanitiser 
when hand washing is not available, preventing cross-contamination 
between foods/surfaces, and sneezing onto the inner elbow, rather 
than onto hands, are just some of the ways to help prevent the 
transmission of any microbial infection[9]. Obtaining clean, safe 
water is also a major problem. Microbes can spread rapidly in 
developing regions that do not have access to clean water and good 
sanitation [10]. Unfortunately, in these areas where the poverty level 
is high, necessary hygiene regimes cannot be achieved. Poverty is 
leading to a greater level of antibiotic misuse, for example, the 
unregulated manufacture of inferior quality drugs, patients sharing 
or not finishing a course of antibiotics, and using out of date drugs. 
These are all too familiar scenarios leading to increased antibiotic 
resistance[11]. 
 
How does climate change fit in? 
Bacteria have also evolved to withstand several different 
environmental factors, such as extreme changes in temperature. 
With climate change at the forefront of recent scientific media 
coverage, it is crucial to link these two significant issues together. 
Generally, an increase in temperature can augment enzyme activity, 
thus increasing bacterial growth. Recent studies have shown 
antibiotic-resistant bacteria are surviving for longer at warmer times 
of the year as global temperatures rise[12]. This proves there is a clear 
association between antibiotic resistance and temperature, meaning 
pathogens may be getting stronger and more resilient over time 
because of global warming[13]. 
 
Where is the money? 
Another big challenge faced by scientists is obtaining the 
funding needed to combat antibiotic resistance. The field of 
antibiotic research and development is grossly underfunded, so 
more investment is needed to support recent improvements and 
solutions being established. While some private companies within 
the industry understand this issue and invest money into an ‘alliance’ 
they have created, the public sector is falling behind drastically. Data 
from 2018 has shown that the total European public sector 
investment fund for antibiotic development totalled roughly €430 
million annually[14]. This is less money than the annual income made 
by the top 10 footballers in the world combined[15], proving 
humanitarian priorities are grossly obscured. Even though the 
European Commission has made funding available through the 
Horizon research and innovation programme, along with AMR 
Action Fund expecting to invest $1 billion in response to the 
antimicrobial resistance (AMR) threat, it is still not enough to make 
the impact that is sorely needed to strengthen the fragile antibiotic 
pipeline which is almost at breaking point[16].  
 
No borders, no boundaries. 
The uncontrolled increase of antibiotic resistance is a serious global 
health concern that affects everyone. Microbes are silent in their 
movement and have no regard for world boundaries or country 
limits. International travel and trade have an obvious impact on 
infectious disease transmission. However, due to the current COVID-
19 situation, there has been a reduction in international travel[17], 
which could possibly have an effect on reducing transmission of 
antibiotic resistant microbes. Limiting travel and trade, conversely, 
is not an ideal reduction method. Therefore, it is up to the worldwide 
community to unite in order to fight these microscopic adversaries, 
as no single initiative by any individual country or region will be 
enough to reverse this trend. All sectors, whether it be political, 
medical, economic, environmental or industrial, have a 
responsibility to help tackle antibiotic resistance, along with the 
other concerning factors associated. Scientists around the world are 
continuing to make advances in the pursuit of new antibiotic 
treatments for infection, and fast detection methods to identify 
antibiotic-resistant genes from pathogens[18]. These endeavours are 
examples of what is needed to restrict and slow down antibiotic 
resistance. 
 
What if a scratch could kill? 
Governments must take steps to invest more time, funding, 
and effort into all aspects of this global crisis. A much-needed 
increase in public spending towards the antibiotic development 
pipeline would relate to an increase in output by scientists. The 
public also needs to be confident that their money is going towards 
combatting an issue that will not only affect us in our lifetime but 
have massive consequences for our children’s lifetime thereafter. As 
antibiotics play a considerable part in healthcare, the ramifications if 
nothing is done are unthinkable. A simple scratch could kill a child, 
cancer treatments could kill a patient, and childbirth could kill an 
expectant mother and her baby[19]. Currently, the global loss of life 
caused by antibiotic resistance is estimated at over 700,000 deaths 
per annum. This is predicted to climb exponentially to over 10 million 
deaths per annum by the year 2050 if no action is taken[20]. These 
figures show the need for scientists and clinicians to start educating 
a broader demographic to understand global and personal impacts 
caused by antibiotic resistance.  
COVID-19 has demonstrated how vulnerable the human race 
is to an infectious agent. The pandemic has been a massive struggle 
for all, putting people and services under enormous pressure. 
However, to prevent this sort of scenario from becoming a regular 
occurrence with even greater loss of life, the global community must 
act now. New solutions are on the horizon, and with every new 
solution, no matter how big or small, comes the possibility to reduce 
death caused by antibiotic resistance, simultaneously bringing hope 
to so many of those already affected by this microbial war. 
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